China’s Drug Innovators Harness AI to Accelerate Discovery, Reduce Costs, and Secure Partnerships

Chinese drug innovators are increasingly employing artificial intelligence (AI) tools to streamline the drug discovery process and reduce costs, aiming to accelerate clinical trials and commercialization. Nanjing’s Genscript Biotech is leveraging its enzyme prediction database and algorithms for DNA sequence modification to identify and optimize drug candidates. Shenzhen-based XTalPi has partnered with US firm DoveTree to globalize its oncology, autoimmune, and neurological drug candidates. Meanwhile, Boston’s Insilico Medicine recently published successful phase two trial results for its AI-discovered drug, rentosertib, targeting idiopathic pulmonary fibrosis. The AI-assisted drug discovery market is projected to grow exponentially, potentially reaching $13 billion by 2032, up from $1.5 billion in 2023, with spending on AI-based clinical research tools expected to surpass $7 billion by 2030. AI is facilitating faster and more accurate processing of extensive biological and clinical trial data, enhancing the overall drug development process.

Source link